Alfasigma's Oral Drug Filgotinib Shows Promise for Axial Spondyloarthritis

BOLOGNA, Italy – May 27, 2026 – Pharmaceutical company Alfasigma has unveiled promising data for a potential new treatment for axial spondyloarthritis (axSpA), a chronic, debilitating inflammatory disease that affects millions worldwide. The results, presented at the prestigious European Alliance of Associations for Rheumatology (EULAR) 2026 congress, suggest the oral, once-daily pill filgotinib could offer a significant new option for patients, many of whom find little relief from existing therapies.

Positive findings from the Phase 3 OLINGUITO trial demonstrated that filgotinib led to sustained improvements in the signs and symptoms of axSpA, including inflammation and overall disease activity. For a patient community often burdened by injectable medications and persistent pain, the prospect of an effective oral treatment marks a potential turning point.

A New Horizon for Spondyloarthritis Patients

Axial spondyloarthritis is a painful inflammatory condition that primarily attacks the spine and the sacroiliac joints connecting the pelvis and lower spine. Often striking people in their 20s and 30s, it causes persistent back pain, severe stiffness, and fatigue that can profoundly diminish quality of life. In advanced cases, it can lead to the fusion of spinal vertebrae, a condition known as ankylosis, causing a permanent loss of mobility.

While treatments exist, including NSAIDs and powerful biologic drugs, data suggests that nearly half of all patients do not respond adequately. This leaves a significant unmet need for new therapies that are both effective and convenient.

The OLINGUITO trial data addresses this gap directly. The study evaluated filgotinib in patients with both radiographic axSpA (where joint damage is visible on X-rays) and non-radiographic axSpA. In both groups, the drug proved superior to a placebo. At week 16, nearly 40% of radiographic patients and 35% of non-radiographic patients taking filgotinib achieved a 40% improvement in symptoms (a standard measure known as ASAS40), compared to just 21% and 18% on placebo, respectively. The improvements were not only statistically significant but also rapid, with some patients feeling effects as early as the first week of treatment. These benefits continued to grow over a full year, with 58-61% of patients achieving low disease activity or remission by week 52.

“Filgotinib delivered rapid improvements in axSpA symptoms, and reductions in bone erosion plus minimal or no progression of ankylosis observed over the 52-week study period indicated limited progression of structural damage,” said Professor Xenofon Baraliakos, Head of Rheumatology at the Rheumazentrum Ruhrgebiet in Germany and a lead investigator on the trial. “These encouraging findings help support the potential of filgotinib as an option for patients living with axSpA at all stages of the disease and with prior exposure and reduced response to existing treatments.”

Alfasigma's Strategic Play in a Crowded Field

The positive results represent a major strategic step for Alfasigma. The Italian pharmaceutical firm acquired the European and UK rights for filgotinib, marketed as Jyseleca, from its original developer Galapagos in a deal finalized in early 2024. The acquisition was a clear signal of Alfasigma's ambition to become a major player in the high-value immunology market.

Jyseleca is already approved in Europe, the UK, and Japan for treating rheumatoid arthritis and ulcerative colitis, but securing an indication for axSpA would significantly expand its market potential. Alfasigma has already submitted the OLINGUITO data to the European Medicines Agency (EMA), putting the drug on a path toward potential approval for this new use.

However, the marketplace is intensely competitive. The axSpA treatment landscape is dominated by blockbuster biologic drugs like AbbVie's Humira and Novartis's Cosentyx. More directly, filgotinib will compete with other oral JAK inhibitors, most notably AbbVie's Rinvoq (upadacitinib), which is already approved for axSpA. Filgotinib's key advantage is its oral, once-daily formulation, which offers a convenient alternative to the self-injections required for most biologic treatments. The trial data showing efficacy in patients who have previously failed biologics could also help carve out a crucial niche.

“People living with axSpA can suffer debilitating symptoms from a young age, and many fail to achieve sustained disease control," said Daniele D'Ambrosio, Chief Development Officer at Alfasigma, in a statement. He noted that the data supports the drug as “a potential new treatment option for adults living with this chronic and progressive disease.”

Navigating the JAK Inhibitor Safety Gauntlet

While the efficacy data is strong, filgotinib's journey is not without challenges. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors, which work by blocking specific enzymes involved in the body's inflammatory response. This targeted approach has revolutionized the treatment of many autoimmune diseases, but it also comes with a history of regulatory scrutiny.

As a class, JAK inhibitors have been linked to an increased risk of serious infections, blood clots, cardiovascular events, and certain cancers. This has led regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the EMA, to issue stringent warnings and usage recommendations for these drugs.

Filgotinib itself has a complicated regulatory past. In 2020, the FDA rejected the drug for rheumatoid arthritis in the U.S., citing safety concerns over the higher 200mg dose and its potential effect on sperm count. The setback ultimately led the original U.S. partner, Gilead Sciences, to abandon development in the country.

Alfasigma states that the safety profile observed in the OLINGUITO trial was consistent with the known profile of filgotinib, with no new safety signals emerging. The trial design also includes a dose-reduction strategy for certain at-risk patients. Nonetheless, the broader class-wide safety concerns will be a primary focus for European regulators as they review the application for axSpA. The EMA's final decision will be a critical milestone, determining whether this promising new option will become available to the thousands of European axSpA patients still searching for effective relief.